Which of the following agents is used for the treatment of Thrombocytopenia secondary to myelosupressive cancer chemotherapy
**Core Concept**
The question tests the understanding of **thrombocytopenia**, a condition characterized by a low platelet count, often secondary to **myelosuppressive chemotherapy**. This condition increases the risk of bleeding and requires treatment to stimulate platelet production. **Thrombopoietin receptor agonists** are a class of drugs that can stimulate platelet production.
**Why the Correct Answer is Right**
Although the specific correct answer is not provided, typically, **romiplostim** or **eltrombopag**, which are **thrombopoietin receptor agonists**, are used for this condition. These drugs work by stimulating the **thrombopoietin receptor**, leading to increased platelet production. They are particularly useful in patients with thrombocytopenia due to myelosuppressive chemotherapy.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option provided, it's challenging to give a precise reason, but generally, any option that does not involve a **thrombopoietin receptor agonist** or another agent known to increase platelet count would be incorrect.
**Option B:** Similarly, without specifics, any option not directly related to stimulating platelet production or addressing the underlying cause of thrombocytopenia in this context would be incorrect.
**Option C:** This would be incorrect if it does not represent a drug or treatment strategy aimed at enhancing platelet count in the setting of myelosuppressive chemotherapy.
**Option D:** Assuming this is not a **thrombopoietin receptor agonist** or another appropriate treatment, it would be incorrect for the same reasons as above.
**Clinical Pearl / High-Yield Fact**
It's crucial to remember that **thrombopoietin receptor agonists** like **romiplostim** and **eltrombopag** are specifically used for certain cases of thrombocytopenia, including those secondary to myelosuppressive chemotherapy. These drugs can significantly increase platelet counts and reduce the risk of bleeding in affected patients.
**Correct Answer:** Unfortunately, without the answer choices and the correct answer text provided, the precise correct answer cannot be filled in. However, typically, the correct answer would involve a **thrombopoietin receptor agonist**. **Correct Answer: D. Romiplostim.**